(CercleFinance.com) – Jefferies remains Buy on Merck shares and maintains its target price of $130.
‘From a macro perspective, Merck has a better earnings-per-share growth profile than its large-cap peers,’ said the broker for whom Merck’s flagship drug, Keytruda, is ‘poorly rated by analysts’.
“Consensus estimates that the Keytruda yield loss in 2028 will cause a $30 billion problem for Merck, but we think Merck is closer to solving that problem than people think,” Jefferies continues.
Merck’s cardiovascular segment is ‘a key component’ of Jefferies’ valuation, with peak sales estimated at ‘$10 billion’.
Finally, Gardasil ‘has a great growth opportunity in China and stable growth levels in the United States’, concludes the analyst.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
